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OBJECTIVES: To explore the proportion of patients with higher risk localized
prostate cancer (PCa) that would become safely biopsy negative 12 months after
non-thermal focal therapy with padeliporfin vascular-targeted photodynamic
therapy (VTP).
METHODS: Multicenter study in a scenario of prostate-specific antigen (PSA)
≤20ng/ml and variable PCa target volumes Gleason pattern 3 or low-volume
secondary Gleason pattern 4, all patients received VTP, consisting of intravenous
4mg/kg padeliporfin activated by light-diffusing fibers in the prostate. The
prostate was biopsied at baseline, months 6 and 12, PSA, patient-reported
functional outcomes and quality of life (QoL) questionnaires were recorded at
baseline, months 3, 6, and 12 and adverse events (AE) throughout the study.
RESULTS: In the intention-to-treat population (n=81), the proportion of patients
with negative biopsies at month 12 was 74% (60/81 patients; 95% CI:
63.1%,83.2%). In the per-protocol population, the proportion was 79% (58/73
patients; 95% CI: 68.4%,88.0%). Questionnaire results indicated a slight
improvement in urinary function and limited deterioration in sexual function. No
difference in QoL was observed over time. A total of 42/81 (52%) patients reported
mild or moderate and 4 of 81 (4.9%) experienced serious AE, all resolved without
sequelae. No phototoxicity, cardiovascular event, fistula or prolonged urinary
incontinence, secondary cancer or death was reported.
CONCLUSIONS: Results support the efficacy, safety, and QoL associated with
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